1 Background: The STEP UP Phase 3b Trial The STEP UP trial was a randomized, double-blind, phase 3b study designed to evaluate the efficacy and safety of a higher weekly dose of subcutaneous semaglutide (7.2 mg) compared to the currently approved 2.4 mg dose
As metabolic processes improve, some patients may notice higher energy levels throughout the day, improved sleep, increased physical endurance, and overall well-being
Several newer antidepressants, such as the SSRI, and fluoxetine have antibacterial activity to treat depression (125, 126)
Yes, switching is medically safe because both contain identical tirzepatide
This is not guideline-based and may reduce efficacy
This project will look at whether uptake of GLP-1/GIP medications varies by factors like age, sex, race, location and income and how these differences may affect womens health outcomes